Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Moodys
Dow
AstraZeneca
Merck

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR IMPAVIDO


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Impavido

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01050907 ↗ Miltefosine to Treat Mucocutaneous Leishmaniasis Completed Knight Therapeutics (USA) Inc Phase 2 2010-05-01 The purpose of this Treatment Investigational New Drug application was to make miltefosine available for mucocutaneous leishmaniasis patients presenting in the United States. If entrance criteria were met, subjects with mucosal or cutaneous leishmaniasis received miltefosine at a targeted dose of 2.5 mg/kg/day for 28 days. During treatment at weeks 1, 2, and 4, the patient returned to the treatment facility to be assessed for adverse events. Blood for transaminase and creatinine values were drawn at the midpoint and at the end of therapy. Patients returned to the treatment facility to be examined clinically at 6 weeks (ie, 2 weeks after the end of therapy), 3 months (2 months after therapy), and 7 months (6 months after treatment) for mucosal leishmaniasis and cutaneous leishmaniasis patients, and also at 13 months (12 months after treatment) for mucosal leishmaniasis patients.
NCT01122771 ↗ Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed International Centre for Diarrhoeal Disease Research, Bangladesh Phase 3 2010-05-01 This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.
NCT01122771 ↗ Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed Shaheed Surhawardy Medical College and Hospital Phase 3 2010-05-01 This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.
NCT01122771 ↗ Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed Drugs for Neglected Diseases Phase 3 2010-05-01 This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.
NCT01377974 ↗ Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis Completed Brasilia University Hospital Phase 2 2009-07-01 The purpose of this study is to determine whether miltefosine is effective in the treatment of mucosal leishmaniasis compared to meglumine antimoniate, the standard treatment.
NCT02011958 ↗ Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Completed Addis Ababa University Phase 3 2014-07-01 The overall objective of this trial is to identify a safe and effective treatment for visceral leishmaniasis (VL) in HIV co-infected Ethiopian patients. Patients will receive either Ambisome alone or Ambisome in combination with Miltefosine. Patients who do not undergo treatment failure will be given a VL prophylactic treatment with Pentamidine one month after the end of the study treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Impavido

Condition Name

Condition Name for Impavido
Intervention Trials
Visceral Leishmaniasis 3
Mucocutaneous Leishmaniasis 2
Cutaneous Leishmaniasis 2
Leishmaniasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Impavido
Intervention Trials
Leishmaniasis 11
Leishmaniasis, Mucocutaneous 4
Leishmaniasis, Visceral 4
Leishmaniasis, Cutaneous 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Impavido

Trials by Country

Trials by Country for Impavido
Location Trials
Sudan 3
United States 3
Ethiopia 3
Bolivia 2
Kenya 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Impavido
Location Trials
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Impavido

Clinical Trial Phase

Clinical Trial Phase for Impavido
Clinical Trial Phase Trials
Phase 3 3
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Impavido
Clinical Trial Phase Trials
Completed 8
Recruiting 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Impavido

Sponsor Name

Sponsor Name for Impavido
Sponsor Trials
Knight Therapeutics (USA) Inc 5
Drugs for Neglected Diseases 5
University of Gondar 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Impavido
Sponsor Trials
Other 19
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Harvard Business School
Colorcon
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.